MOSCOW (MRC) -- Clariant is set to expand its Care Chemicals facility in Daya Bay, Huizhou, China, to boost its support for pharmaceutical, personal care, home care, and industrial application customers, said the company.
The CHF 80 million investment will see capacity increases for existing products as well as the introduction of new products by the end of 2024. By successfully obtaining the drug GMP certificate, the Clariant Daya Bay manufacturing site has become the first API manufacturer in China with certified polyethylene glycol Polyglykol 3350. The site will also become a new global hub for Clariant’s healthcare business support, speeding up the supply of high-quality ingredients for life-changing medicines.
“The successful production and registration of the pharmaceutical grade of PEGs are great examples of how resilient and dedicated Clariant is to growing in our strategic dedicated business segment and supporting our customers,” said Zhigang Miao, Head of Industrial Applications, Clariant Care Chemical.
Clariant will also expand existing production capacity for its Ethylene Oxide Derivatives (EODs) and a broader chemical portfolio at Daya Bay. As a result, it will step up its production of more sustainable ingredients that can help customers advance their environmental targets and create differentiated, more sustainable solutions to meet sector demands. The EcoTain®-labelled, plant-based Hostapon® mild surfactant for example supports Personal Care brands and formulators in developing milder, cleaner beauty in applications such as solid beauty bars, body washes and cream-type shampoos.
As per MRC, Clariant will invest Swiss francs (Swfr) 80m (USD86m) to expand its Care Chemicals facility at Daya Bay in China’s Guangdong province, boosting support for pharmaceutical, personal care, home care and industrial application customers. This investment will increase Clariant’s production capacity for existing products as well as the introduction of new products by the end of 2024. Clariant also aims for the site to become a new global hub for its healthcare business, saying it believes China would remain a growth driver for many chemicals.